<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163761</url>
  </required_header>
  <id_info>
    <org_study_id>AH226/02</org_study_id>
    <nct_id>NCT00163761</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Outpatient Therapy for Lymphoma</brief_title>
  <official_title>A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted
      outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and
      pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma has been increasing in incidence annually for the past several decades and the
      majority of patients relapse after first line therapy. A variety of 'salvage chemotherapy'
      treatments are available that are usually inpatient-based treatments associated with
      significant haematological toxicity. Furthermore, all patients are treated in the same manner
      despite the fact that some patients will do well irrespective of the type of salvage therapy
      whereas others will do badly no matter what is done. During 2001-2002 we undertook a pilot
      study in 40 such patients using an outpatient-based salvage therapy with 2 newer chemotherapy
      drugs, vinorelbine and gemcitabine. Over 75% of all treatments were successfully delivered on
      an outpatient basis with response rates similar to historical controls. We now propose to
      expand on these initial findings by modifying the outpatient approach for those patients with
      less favourable prognostic features, that is, patients will be stratified to differing
      therapies but with the majority still receiving the proven vinorelbine-gemcitabine
      combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy (overall response rate) of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim).</measure>
    <time_frame>After two cycles and after four cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety,</measure>
    <time_frame>Days 1 and 8 for every cycle, days 10,12,14, and 16 for first cycle.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival,</measure>
    <time_frame>After 2 cycles, 4 cyles and every 3 or 4 months for 12 months. Then every 6 months until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival,</measure>
    <time_frame>every 3 or 4 months for 12 months. Then every 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and planned dose-on-time.</measure>
    <time_frame>After two cycles and after four cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>Commence VGF treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commence F-GIV treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, vinorelbine, ifosfamide, filgastrim</intervention_name>
    <description>Drug</description>
    <arm_group_label>Commence F-GIV treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, vinorelbine, filgastrim</intervention_name>
    <description>Drug</description>
    <arm_group_label>Commence VGF treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  relapsed or primary refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD)

          -  ECOG 0 - 2

          -  written informed consent

        Exclusion criteria:

          -  Intention to proceed with any form of transplant therapy following fewer than 2 cycles
             of protocol salvage therapy

          -  bilirubin &gt; 50Î¼mol/litre unless secondary to lymphoma

          -  creatinine &gt; 2 x upper limit of normal unless secondary to lymphoma, absolute
             neutrophil count &lt;0.5 x 109/litre and / or platelets &lt; 50 x 109/litre unless secondary
             to lymphoma

          -  relapse within 6 months of a prior transplant procedure (autologous or allogeneic)

          -  known sensitivity to E coli derived preparations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Spencer, Assoc. Prof</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

